The case for & against
Bull & Bear analysis
Bullish
Akoya Biosciences, Inc. (NASDAQ: AKYA) is a leading innovator in the spatial biology sector, specializing in high-plex tissue imaging solutions aimed at enhancing drug discovery and diagnostics. Positioned strategically within the biopharmaceutical landscape, Akoya’s products, such as the PhenoCycler and PhenoImager systems, emphasize transformation in biomarker discovery and informed clinical applications. As the demand for precision medicine increases, Akoya is well-placed to capitalize on significant growth opportunities, particularly within oncology and translational research.
Bull says
- ↑Q3 2023 revenue $25.2M (+34% YoY), driven by reagent growth.
- ↑Reagent sales hit $7M in Q1 2024 (+23% YoY), boosting recurring revenue.
- ↑Gross margin reached 62.7% in Q4 2023 via cost optimization.
- ↑Installed base expanded to 1,299 instruments, fueling consumable sales.
- ↑Companion diagnostics pipeline with biopharma partners expands TAM.
- ↑Positive factor profile: strong earnings yield, momentum, and ROE.
Bear says
- ↓Q1 2024 revenue declined 14% YoY due to slower instrument orders.
- ↓Operating expenses rose, leading to an $11.1M loss in Q2 2024.
- ↓Extended sales cycles amid macro pressures hinder timely revenues.
- ↓High dependence on reagent growth risks margins if instrument sales lag.
- ↓Competition from Illumina, 10x Genomics, and emerging players intensifies.
- ↓Risk factors include weak profitability metrics, elevated short interest, and low liquidity.
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 09-07-2026bullish
Transcript signals
Bull points
- record-breaking revenue of $25.2 million, representing a strong 34% growth compared to the previous year
- $15.3 million in the third quarter, representing a 40% growth over the prior year period
- gross margin has now grown to 60.6% for the third quarter
Read full transcript analysis ›